NIH PAR · NCI · R01
PAR-25-081: National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
Through this Notice of Funding Opportunity, the National Cancer Institute (NCI) seeks research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may…
- NOFO number
- PAR-25-081
- Type
- PAR
- Activity code
- R01
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Required
- Posted
- Nov 12, 2024
- Opens
- Jan 5, 2025
- Expires
- Jan 8, 2027
PAR-25-081 due dates
No application due dates remain in the listed cycles. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 05, 2025 | March 05, 2025 * | May 07, 2025 * | July 2025 | October 2025 | December 2025 |
| June 05, 2025 | July 05, 2025 * | September 07, 2025 * | November 2025 | January 2026 | April 2026 |
| October 05, 2025 | November 05, 2025 * | January 07, 2026 * | March 2026 | May 2026 | July 2026 |
| February 05, 2026 | March 05, 2026 * | May 07, 2026 * | July 2026 | October 2026 | December 2026 |
| June 05, 2026 | July 05, 2026 * | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 05, 2026 | November 05, 2026 * | Not Applicable | March 2027 | May 2027 | July 2027 |
Projects funded under PAR-25-081
NIH RePORTER lists 29 projects funded under PAR-25-081 in FY2022–FY2026, with $17.9M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
29
Distinct projects, FY2022–FY2026
New awards
24
Type 1 (new project) award records
NIH funding
$17.9M
Award dollars under PAR-25-081, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 29 | 24 | $17.9M |
Institutions with the most funding
- Washington University$2.4M · 4 projects
- Utah State Higher Education System--University of Utah$1.3M · 2 projects
- Dana-Farber Cancer Inst$1.1M · 2 projects
- University of Tx MD Anderson Can Ctr$829K · 2 projects
- Mayo Clinic Rochester$748K · 1 project
- St. Jude Children's Research Hospital$737K · 1 project
- Sloan-Kettering Inst Can Research$715K · 1 project
- Cedars-Sinai Medical Center$710K · 1 project
Most recent new awards
- Leveraging high glucose to prevent pancreatic cancer progression (opens NIH RePORTER)
Case Western Reserve University · 1R01CA305024-01A1 · NCI · Notice Sep 16, 2026
$608KR01
- Targeting Tumor Intrinsic and Extrinsic Survival Signaling to Overcome Resistance to Radiation Therapy in Pancreatic Cancer. (opens NIH RePORTER)
Washington University · 1R01CA303033-01A1 · NCI · Notice Sep 14, 2026
$603KR01
- Enhancing CAR-T cell therapy for DLBCL (opens NIH RePORTER)
Washington University · 1R01CA286488-01A1 · NCI · Notice Sep 3, 2026
$549KR01
- Imaging-Computational Framework for Guiding Treatment of HGG: an oHSV clinical trial (opens NIH RePORTER)
University of Alabama at Birmingham · 1R01CA313500-01 · NCI · Notice Sep 3, 2026
$644KR01
- Optimizing the dosing of post-transplantation cyclophosphamide for peripheral blood stem cell transplantation (opens NIH RePORTER)
Fred Hutchinson Cancer Center · 1U01CA303465-01A1 · NCI · Notice Sep 1, 2026
$695KU01
- Prospective Dynamic BH3 Profiling for Clinical Use in Relapsed or Refractory AML (opens NIH RePORTER)
Dana-Farber Cancer Inst · 1R37CA304011-01A1 · NCI · Notice Sep 1, 2026
$389KR37
What its predecessor PAR-24-085 funded
PAR-25-081 reissues PAR-24-085. Its funding history is the best guide to who wins under this program: 24 projects and $30.8M in FY2022–FY2026.
Projects funded
24
Distinct projects, FY2022–FY2026
New awards
22
Type 1 (new project) award records
NIH funding
$30.8M
Award dollars under PAR-24-085, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 24 | 22 | $17.7M |
| FY2026 | 21 | 0 | $13.2M |
Institutions with the most funding
- Sloan-Kettering Inst Can Research$5.5M · 4 projects
- University of Pennsylvania$5.2M · 4 projects
- Beckman Research Institute/City of Hope$4.3M · 3 projects
- Oregon Health & Science University$2.5M · 1 project
- Johns Hopkins University$2.2M · 2 projects
- University of Tx MD Anderson Can Ctr$1.8M · 1 project
- University of Southern California$1.4M · 1 project
- University of California, San Diego$1.3M · 1 project
Most recent new awards
- Advancing next-generation CAR-NK therapies targeting CD5 positive T cell malignancies to the clinic (opens NIH RePORTER)
University of Tx MD Anderson Can Ctr · 1R01CA303579-01 · NCI · Notice Sep 18, 2025
$1.8MR01
- DLL3-targeted IL18-secreting CAR T cells in Small Cell Lung Cancer (opens NIH RePORTER)
Sloan-Kettering Inst Can Research · 1R01CA303470-01 · NCI · Notice Aug 22, 2025
$717KR01
- Fluorescence guided nerve sparing during colorectal cancer surgery using local application of a near infrared nerve fluorophore (opens NIH RePORTER)
Oregon Health & Science University · 1R01CA303975-01 · NCI · Notice Aug 15, 2025
$2.5MR01
- Clinical Translation of a Choline-targeted NIR dye to guide lung cancer resection (opens NIH RePORTER)
University of Pennsylvania · 1R01CA293595-01A1 · NCI · Notice Aug 15, 2025
$657KR01
- A New Ultrasound Probe and Robot for Prostate Biopsy and Focal Therapy (opens NIH RePORTER)
Johns Hopkins University · 1R01CA303859-01 · NCI · Notice Jul 28, 2025
$513KR01
- Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer. (opens NIH RePORTER)
Sloan-Kettering Inst Can Research · 1R01CA296285-01A1 · NCI · Notice Jul 23, 2025
$482KR01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-081. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Notices of Special Interest (NOSIs)
NIH has attached 1 NOSI to PAR-25-081; none are active now. A NOSI flags a topic an institute wants to fund through this NOFO.
Award terms
- Application types allowed
- NewRenewalResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are limited to no more than 499,999 in direct costs per year. 
- Project period
- The maximum project period is 5 years.   NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-24-085.
- Companion NOFOs: PAR-25-167.
Other open NOFOs for R01
- PAR-25-336Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)NCI · next due Nov 16, 2026
- PAR-27-072Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-337Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-338Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PAR-25-243Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PA-25-172Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.